{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-21-002587","form_type":"8-K","ticker":"UTMD","cik":"0000706698","company_name":"UTAH MEDICAL PRODUCTS INC","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.308733+00:00","generated_at":"2026-06-28T18:12:24.800357+00:00","sec_items":["2.02","9.01","99.1"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"UTMD Q3 2021 EPS $1.150, revenue up 20%; 9M non-GAAP EPS $3.021, up 46%","bullets":["Q3 2021 net income $4.2M (33.5% of sales), up 43.4% YoY; diluted EPS $1.150.","9M 2021 US GAAP net income $10.7M, up 44.3%; non-GAAP net income $11.0M, up 45.1%.","Cash and investments at Sep 30, 2021: $64.3M, up from $51.6M at Dec 31, 2020.","Management expects FY2021 adjusted EBITDA >$26M ($28M for 2022).","Dividend increased to $0.285/share; total 9M dividends $3.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-21-002587","json":"https://secwatch.observer/filing/0001096906-21-002587.json","markdown":"https://secwatch.observer/filing/0001096906-21-002587.md","text":"https://secwatch.observer/filing/0001096906-21-002587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/706698/000109690621002587/0001096906-21-002587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/706698/000109690621002587/utmd-20211026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:12:24.800357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}